TISIDB

Summary
Symbol	IRX3
Name	iroquois homeobox 3
Aliases	IRX-1; IRXB1; homeodomain protein IRXB1; iroquois homeobox protein 3; Iroquois-class homeodomain protein IRX ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF05920 Homeobox KN domain
Function	Transcription factor. Involved in SHH-dependent neural patterning. Together with NKX2-2 and NKX6-1 acts to restrict the generation of motor neurons to the appropriate region of the neural tube. Belongs to the class I proteins of neuronal progenitor factors, which are repressed by SHH signals. Involved in the transcriptional repression of MNX1 in non-motor neuron cells (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001655 urogenital system development GO:0001656 metanephros development GO:0001822 kidney development GO:0001838 embryonic epithelial tube formation GO:0003002 regionalization GO:0007379 segment specification GO:0007389 pattern specification process GO:0007498 mesoderm development GO:0009954 proximal/distal pattern formation GO:0010720 positive regulation of cell development GO:0010721 negative regulation of cell development GO:0016331 morphogenesis of embryonic epithelium GO:0035148 tube formation GO:0035239 tube morphogenesis GO:0035282 segmentation GO:0045665 negative regulation of neuron differentiation GO:0045666 positive regulation of neuron differentiation GO:0050768 negative regulation of neurogenesis GO:0050769 positive regulation of neurogenesis GO:0051961 negative regulation of nervous system development GO:0051962 positive regulation of nervous system development GO:0060562 epithelial tube morphogenesis GO:0060993 kidney morphogenesis GO:0061004 pattern specification involved in kidney development GO:0061326 renal tubule development GO:0061333 renal tubule morphogenesis GO:0072001 renal system development GO:0072006 nephron development GO:0072009 nephron epithelium development GO:0072028 nephron morphogenesis GO:0072047 proximal/distal pattern formation involved in nephron development GO:0072048 renal system pattern specification GO:0072070 loop of Henle development GO:0072073 kidney epithelium development GO:0072078 nephron tubule morphogenesis GO:0072079 nephron tubule formation GO:0072080 nephron tubule development GO:0072081 specification of nephron tubule identity GO:0072086 specification of loop of Henle identity GO:0072088 nephron epithelium morphogenesis GO:0072175 epithelial tube formation
Molecular Function	-
Cellular Component	GO:0030424 axon

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	IRX3
Name	iroquois homeobox 3
Aliases	IRX-1; IRXB1; homeodomain protein IRXB1; iroquois homeobox protein 3; Iroquois-class homeodomain protein IRX ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between IRX3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	IRX3
Name	iroquois homeobox 3
Aliases	IRX-1; IRXB1; homeodomain protein IRXB1; iroquois homeobox protein 3; Iroquois-class homeodomain protein IRX ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of IRX3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	IRX3
Name	iroquois homeobox 3
Aliases	IRX-1; IRXB1; homeodomain protein IRXB1; iroquois homeobox protein 3; Iroquois-class homeodomain protein IRX ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of IRX3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.066	0.904
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.586	0.711
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.304	0.822
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.259	0.749
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.414	0.793
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.07	0.973
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.095	0.842
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.641	0.479
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.747	0.378
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.577	0.726
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.05	0.984
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.855	0.00526

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of IRX3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	IRX3
Name	iroquois homeobox 3
Aliases	IRX-1; IRXB1; homeodomain protein IRXB1; iroquois homeobox protein 3; Iroquois-class homeodomain protein IRX ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IRX3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	IRX3
Name	iroquois homeobox 3
Aliases	IRX-1; IRXB1; homeodomain protein IRXB1; iroquois homeobox protein 3; Iroquois-class homeodomain protein IRX ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IRX3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IRX3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	IRX3
Name	iroquois homeobox 3
Aliases	IRX-1; IRXB1; homeodomain protein IRXB1; iroquois homeobox protein 3; Iroquois-class homeodomain protein IRX ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IRX3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	IRX3
Name	iroquois homeobox 3
Aliases	IRX-1; IRXB1; homeodomain protein IRXB1; iroquois homeobox protein 3; Iroquois-class homeodomain protein IRX ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of IRX3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	IRX3
Name	iroquois homeobox 3
Aliases	IRX-1; IRXB1; homeodomain protein IRXB1; iroquois homeobox protein 3; Iroquois-class homeodomain protein IRX ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between IRX3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	IRX3
Name	iroquois homeobox 3
Aliases	IRX-1; IRXB1; homeodomain protein IRXB1; iroquois homeobox protein 3; Iroquois-class homeodomain protein IRX ......
Chromosomal Location	16q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting IRX3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse IRX3